MYD88 and lymphoma: Furthermore, other pathways such as NFkB are activated in cHL and PMBL, and we have shown previously that HSP110 sustains the activation of these pathways through MyD88 stabilization [33] The MyD88 mutation is absent in cHL and PMBL, but other HSPs have been implicated in the NFkB pathways in lymphomas, for instance HSP90, whose inhibition reduces Ikkα, β and δ [47].